Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis
Metrics: PDF 677 views | HTML 1135 views | ?
Weimin Xie1,*, Li Ning1,*, Yuenan Huang2, Yan Liu3, Wen Zhang1, Yingchao Hu1, Jinghe Lang1 and Jiaxin Yang1
1Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2Department of General Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin, China
3Department of Epidemiology and Statistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing, China
*These authors contributed equally to this work
Jiaxin Yang, email: firstname.lastname@example.org
Keywords: gynecologic cancer, statin, survival outcomes, meta-analysis
Received: March 22, 2017 Accepted: April 11, 2017 Published: April 19, 2017
Previous studies investigating the association between statin use and survival outcomes in gynecologic cancers have yielded controversial results. We conducted a systematic review and meta-analysis to evaluate the association based on available evidence. We searched the databases of the Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and PubMed from inception to January 2017. Studies that evaluated the association between statin use and survival outcomes in gynecologic cancers were included. Pooled hazard ratios (HRs) for overall survival, disease-specific survival and progression-free survival were calculated using a fixed-effects model. A total of 11 studies involving more than 6,920 patients with endocrine-related gynecologic cancers were identified. In a meta-analysis of 7 studies involving 5,449 patients with endocrine-related gynecologic cancers, statin use was linked to improved overall survival (HR, 0.71; 95% confidence interval [CI], 0.63 to 0.80) without significant heterogeneity (I2 = 33.3%). Statin users also had improved disease-specific survival (3 studies, HR, 0.72; 95% CI, 0.58 to 0.90, I2 = 35.1%) and progression-free survival (3 studies, HR, 0.68; 95% CI, 0.49 to 0.93, I2 = 33.6%) in endocrine-related gynecologic cancers. Our findings support that statin use has potential survival benefits for patients with endocrine-related gynecologic cancers. Further large-scale prospective studies are required to validate our findings.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.